Identification and Isolation of Novel Sugar-Like RNA Protecting Materials: Glycylglycerins from Pluripotent Stem Cells

  • Shi-Lung Lin
Part of the Methods in Molecular Biology book series (MIMB, volume 1733)


Pluripotent stem cells are a resourceful treasure box for regenerative medicine. They contain a large variety of novel materials useful for designing and developing new medicines and therapies directed against many aging-associated degenerative disorders, including Alzheimer’s disease, Parkinson’s disease, stroke, diabetes, osteoporosis, and cancers. Currently, identification of these novel stem cell-specific materials is one of major breakthroughs in the field of stem cell research. Particularly, since the discovery of induced pluripotent stem cells (iPSC) in year 2006, the methods of iPSC derivation further provide an unlimited resource for screening, isolating, and even producing theses novel stem cell-specific materials in vitro. Using iPSCs, we can now prepare high quality and quantity of pure stem cell-specific agents for testing their therapeutic functions in treating various illnesses. These newly found stem cell-specific agents are divided into four major categories, including proteins, saccharides, nucleic acids, and small molecules (chemicals). In this article, we herein disclose one of the methodologies for isolating and purifying glycylglycerins—a group of glycylated sugar alcohols that protect hairpin-like microRNA precursors (pre-miRNA) and some of tRNAs in pluripotent stem cells. In view of such a unique RNA-protecting feature, glycylglycerins may be used to preserve and deliver functional small RNAs, such as pre-miRNAs and small interfering RNAs (siRNA), into human cells for eliciting their specific RNA interference (RNAi) effects, which may greatly advance the use of RNAi technology for treating human diseases.

Key words

Induced pluripotent stem cell (iPSC) MicroRNA (miRNA) RNA interference (RNAi) Glycylglycerin 


  1. 1.
    Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY (2008) Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 14:2115–2124CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT (2011) Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res 39:1054–1065CrossRefPubMedGoogle Scholar
  3. 3.
    Lin SL, Ying SY (2012) Mechanism and method for generating tumor-free iPS cells using intronic microRNA miR302 induction. In: Ying SY (ed) MicroRNA Protocols, 2nd edn. Springer Publishers press, New York, pp 295–324Google Scholar
  4. 4.
    Chang-Lin S, Hung A, Chang DC, Lin YW, Ying SY, Lin SL (2016) Novel glycylated sugar alcohols protect ESC-specific microRNAs from degradation in iPS cells. Nucleic Acids Res 44:4894–4906CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen SKJ, Lin SL (2013) Recent patents on microRNA-induced pluripotent stem cell generation. Recent Pat Regen Med 3:5–16Google Scholar
  6. 6.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676CrossRefPubMedGoogle Scholar
  7. 7.
    Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920CrossRefPubMedGoogle Scholar
  8. 8.
    Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318–324CrossRefPubMedGoogle Scholar
  9. 9.
    Li HH, Lin SL, Huang CN, Lu FJ, Chiu PY, Huang WN, Lai TJ, Lin CL (2016) miR-302 attenuates amyloid-β-induced neurotoxicity through activation of Akt signaling. J Alzheimers Dis 50:1083–1098CrossRefPubMedGoogle Scholar
  10. 10.
    Lin SL, Chang-Lin S, Lin YW, Chang D (2014) Use of novel monosaccharide-like glycylated sugar alcohol compositions for designing and developing anti-diabetic drugs. US patent application number 14/585978Google Scholar
  11. 11.
    Lin SL, Chang D, Ying SY, Leu D, Wu DTS (2010) MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of CDK2 and CDK4/6 cell cycle pathways. Cancer Res 70:9473–9482CrossRefPubMedGoogle Scholar
  12. 12.
    Lin SL, Lin YW (2016) Sugar alcohol-based compositions for delivering nucleic acid-based drugs in vivo and in vitro. US patent number 9387251Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Division of Regenerative MedicineWJWU and LYNN Institute for Stem Cell ResearchSanta Fe SpringsUSA

Personalised recommendations